Status:
COMPLETED
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
Lead Sponsor:
GlaxoSmithKline
Conditions:
Nausea and Vomiting, Postoperative
Postoperative Nausea and Vomiting
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- History of PONV (postoperative nausea and vomiting) and/or motion sickness.
- Have not smoked for the last 6 months.
- Having certain abdominal, breast, thyroid or shoulder surgery.
- Exclusion criteria:
- Pregnant or breastfeeding.
- Have certain pre-existing medical conditions or take certain medications.
Exclusion
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
515 Patients enrolled
Trial Details
Trial ID
NCT00334152
Start Date
March 1 2006
End Date
July 1 2006
Last Update
March 23 2017
Active Locations (70)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Fairhope, Alabama, United States, 36532
2
GSK Investigational Site
Mobile, Alabama, United States, 36608
3
GSK Investigational Site
Montgomery, Alabama, United States, 36106
4
GSK Investigational Site
Little Rock, Arkansas, United States, 72205